10539-19-2

Basic information

• Product Name: moxaverine
• Synonyms: Isoquinoline, 3-ethyl-6,7-dimethoxy-1-(phenylmethyl)-;Moxaverina;Moxaverina [inn-spanish];1-Benzyl-3-ethyl-6,7-dimethoxyisoquinoline hydrochloride;moxaverine;1163-37-7 (Hydrochloride);3-Ethyl-1-benzyl-6,7-dimethoxyisoquinoline;Einecs 234-117-5
• CAS NO: 10539-19-2
• Molecular Formula: C₂₀H₂₁NO₂
• Molecular Weight: 307.391
• EINECS: 234-117-5
• Mol File: 10539-19-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 71-72.5°
• Boiling Point: 441.2°Cat760mmHg
• Flash Point: 158.7°C
• Appearance: /
• Density: 1.109g/cm³
• Vapor Pressure: 1.44E-07mmHg at 25°C
• Refractive Index: 1.597
• PKA: 7.12±0.50(Predicted)
• CAS DataBase Reference: moxaverine(CAS DataBase Reference)
• NIST Chemistry Reference: moxaverine(10539-19-2)
• EPA Substance Registry System: moxaverine(10539-19-2)

Safety Data

• Hazardous Substances Data: 10539-19-2(Hazardous Substances Data)

Usage

General Description

Moxaverine is a synthetic compound with smooth muscle relaxant properties. It is known to work specifically on the smooth muscles of the blood vessels and gastrointestinal tract, helping to alleviate conditions such as peripheral vascular disease, Raynaud's phenomenon, and irritable bowel syndrome. Moxaverine is believed to exert its effects by inhibiting the action of phosphodiesterase enzymes, which normally break down the molecule cyclic adenosine monophosphate (cAMP). By increasing the levels of cAMP, moxaverine promotes relaxation of smooth muscle cells, leading to improved blood flow and reduced gastrointestinal contractions. This mechanism of action suggests that moxaverine may be a valuable therapeutic option for various conditions characterized by smooth muscle spasm and reduced blood flow.

InChI:InChI=1/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3

Upstream product

• 536-74-3 phenylacetylene 
• 95314-73-1 methyl 1-methyl-2-propynyl carbonate 
• 103-80-0 phenylacetyl chloride 
• 3141-93-3 4',5'-dimethoxydeoxybenzoin 
• 103-82-2 phenylacetic acid 

Relevant articles and documents

Redox-Neutral Manganese(I)-Catalyzed C?H Activation: Traceless Directing Group Enabled Regioselective Annulation

A strategy is reported in which traceless directing groups (TDGs) are used to promote the redox-neutral MnI-catalyzed regioselective synthesis of N-heterocycles. Alkyne coupling partners bearing a traceless directing group, which serves as both the chelator and internal oxidant, were used to control the regioselectivity of the annulation reactions. This operationally simple approach is highly effective with previously challenging unsymmetrical alkyne systems, including unbiased dialkyl alkynes, with perfect regioselectivity. The simple conditions and the ability to carry out synthesis on a gram scale underscore the usefulness of this method. The application of this strategy in the concise synthesis of the bioactive compound PK11209 and the pharmaceutical moxaverine is also described.

Rh(III)-catalyzed C-H activation/cyclization of oximes with alkenes for regioselective synthesis of isoquinolines

A Rh(iii)-catalyzed C-H activation/cyclization of oximes and alkenes for facile and regioselective access to isoquinolines has been developed. This protocol features mild reaction conditions and easily accessible starting materials, and has been applied to the concise synthesis of moxaverine. A kinetic isotope effect study was conducted and a plausible mechanism was proposed.